Clavis Pharma announces encouraging interim results of Phase II trial with elacytarabine in combination with idarubicin

Clavis Pharma announces encouraging interim results of Phase II trial with elacytarabine in combination with idarubicin in patients with early stage acute myeloid lymphoma (AML)

Biomarker analysis suggests hENT1 levels may identify patients for whom elacytarabine could be an effective treatment

Oslo, Norway, 17 August 2011

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces encouraging interim efficacy data from its Phase II clinical trial with elacytarabine in combination with idarubicin in patients with acute myeloid lymphoma (AML) who have failed cytarabine (ara-C)-containing first-course chemotherapy. Elacytarabine is a novel, patented lipid-conjugated form of the anti-cancer drug cytarabine created by Clavis Pharma using its Lipid Vector Technology (LVT).

The interim results found that treatment with the elacytarabine/idarubicin combination showed promising clinical activity with a complete remission (CR/CRi*) rate of close to 50% in patients who failed to respond to cytarabine-containing first-course treatment (11 of 23 evaluated patients).  As expected, these responses are independent of the patient's hENT1 status. hENT1 (human Equilibrative Nucleoside Transporter 1) is a protein expressed on the surface of cancer cells that has been shown to be important for the uptake and efficacy of cytarabine.

30 patients have been assessed for hENT1 expression level at time of initial AML diagnosis before standard cytarabine treatment. Preliminary results indicate that approximately 50% of patients have low hENT1 expression. Of the patients with low hENT1, only approximately one third responded to conventional cytarabine-containing therapy, while two thirds the patients with high hENT1 responded.

The main objective of the ongoing 50-patient trial is to study response rates to the combination treatment and the relationship of outcome to the patient's hENT1 status. The study is being conducted at leading haematology clinics in the USA and Europe.

An abstract describing these interim results has been submitted for presentation at the upcoming American Society of Haematology meeting in San Diego, CA, USA (10-13 December 2011).

Olav Hellebø, Clavis Pharma CEO, also commented: "The interim results have shown that elacytarabine in combination with idarubicin elicits a positive therapeutic effect in a substantial proportion of AML patients for whom first-course cytarabine treatment failed. This is very encouraging and, with the hENT1 data seen, highlights the potential of our LVT drugs to offer an effective treatment option to patients who may not respond to current standard cancer therapies."

*CR/CRi - complete remission including complete remission with incomplete blood count recovery.

About Clavis Pharma
Clavis Pharma ASA is a late clinical stage oncology discovery and drug development company based in Oslo, Norway with a portfolio of novel anti-cancer drugs in development. These patented New Chemical Entities (NCEs) are novel, improved versions of commercially successful drugs, made using Clavis Pharma's Lipid Vector Technology (LVT) chemistry. Data generated suggests these potential breakthrough products may offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties, greater tissue penetration, altered metabolism and, in certain cases, additional modes of action. 

Clavis Pharma's has several drug candidates in formal development studies:

  • Elacytarabine, a leukaemia drug, currently in a randomized, controlled Phase III study in late-stage acute myeloid leukaemia;
  • CP-4126, is currently in a pivotal clinical study compared to gemcitabine for the 1st line treatment of pancreatic cancer and a Phase II trial for 2nd line treatment for pancreatic cancer in patients refractory to 1st line gemcitabine treatment;
  • CP-4200, an azacitidine derivative, in preclinical development for myelodysplastic syndrome (MDS), a disease that is often a precursor to leukaemia. 

Clavis Pharma intends to commercialise its products through strategic alliances and partnerships with experienced oncology businesses and, where and when commercially appropriate, by establishing its own sales and marketing capabilities. CP-4126 is licensed to Clovis Oncology globally. Clavis Pharma has an option to co-promote CP-4126 in Europe.

Suggested Articles

The takeover centers on a near-approval anti-CGRP antibody that could address Lundbeck’s need for near-term revenue drivers.

Amplyx revealed early data for its lead program in candidemia and licensed a phase 2-ready program for BK virus infection from Novartis.

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”